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Abstract 24 
Elimination of virus-infected cells by cytotoxic lymphocytes is triggered by activating receptors, among 25 
which NKG2D and DNAM-1/CD226 play an important role. Their ligands - MICA/B and ULBP1-6 26 
(NKG2DL), Nectin-2/CD112 and PVR/CD155 (DNAM-1L) - are often induced on virus-infected cells, 27 
though some viruses, including Human Cytomegalovirus (HCMV), can block their expression. Here, we 28 
report that infection of different cell types with laboratory or low-passage HCMV strains upregulated 29 
MICA, ULBP3 and PVR, with NKG2D and DNAM-1 playing a role in NK cell-mediated lysis of 30 
infected cells. Inhibition of viral DNA replication with phosphonoformic acid did not prevent ligand 31 
upregulation, thus indicating that early phases of HCMV infection are involved in ligand increase. 32 
Indeed, the major immediate early (IE) proteins IE1 and IE2 stimulated the expression of MICA and 33 
PVR, but not ULBP3. IE2 directly activated MICA promoter, via its binding to an IE2-responsive element 34 
we identified within the promoter, and that is conserved among different alleles of MICA. Both IE 35 
proteins were instead required for PVR up-regulation, via a mechanism independent of IE DNA-binding 36 
activity. Finally, inhibiting IE protein expression during HCMV infection confirmed their involvement in 37 
ligand increase. We also investigated the contribution of the DNA damage response (DDR), a pathway 38 
activated by HCMV and implicated in ligand regulation. However, silencing of ATM, ATR and DNA-PK 39 
kinases did not influence ligand expression. Overall, these data reveal that MICA and PVR are directly 40 
regulated by HCMV IE proteins, and this may be crucial for the onset of an early host anti-viral response. 41 
42 
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Introduction 43 
Human cytomegalovirus (HCMV) is an endemic β-herpesvirus that does not cause clinically obvious 44 
disease in healthy individuals, where it establishes a life-long latency. In immunocompromised hosts, 45 
such as AIDS patients and organ transplant recipients, infection often becomes clinically apparent and can 46 
cause life-threatening diseases. HCMV is also the leading viral cause of congenital infections and birth 47 
defects (1,2). HCMV disseminates throughout the body, with a broad range of different cell types 48 
supporting productive viral infection (3). In addition, it induces a plethora of immunomodulatory 49 
pathways to subvert the host innate and adaptive immune responses (2). To date, few anti-viral drugs are 50 
available, but long-term treatment is frequently associated with toxic side effects and the emergence of 51 
drug-resistant mutants (4,5). 52 
Clearly, in the absence of an effective and preemptive HCMV vaccine, additional therapeutic agents are 53 
urgently needed, and strategies to potentiate anti-HCMV immune response could be also a valuable 54 
alternative approach. 55 
With this rationale, we investigated whether molecules capable of activating cytotoxic lymphocytes may 56 
be positively regulated following HCMV infection, thus enhancing the recognition and elimination of 57 
infected cells. In particular, we focused on the ligands of NKG2D and DNAM-1/CD226, two activating 58 
receptors expressed by all cytotoxic lymphocytes. NKG2D delivers a potent activating signal and plays a 59 
prominent role in the recognition and elimination of infected cells (6,7). In humans, NKG2D ligands 60 
(NKG2DL) are the MHC-I-related molecules MICA, MICB, and the ULBP proteins (ULBP1-6), whose 61 
expression is restricted in normal cells, but it can be rapidly induced upon cellular stress, including a viral 62 
infection (6,7). DNAM-1 receptor is essential to NK cell-dependent anti-tumor immunity (8) and its role 63 
in the response to viral infections is also starting to emerge (9-12). It is an adhesion molecule and the 64 
binding to its ligands, Poliovirus Receptor (PVR) (CD155) and Nectin-2 (CD112), promotes leukocyte 65 
migration, as well as effector responses of both NK and T cells (8,13). HCMV evolved specific strategies 66 
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to block the functions of NKG2D and DNAM-1. Indeed, there is an array of viral molecules (UL16, 67 
UL141, UL142, US18 and US20, US9, miRNA-UL112) targeting both NKG2DL and DNAM-1L, and 68 
impairing recognition and elimination of HCMV-infected cells by NK cells and other NKG2D+ and 69 
DNAM-1+ cells (14-17). In contrast, it is still debated if and how HCMV up-regulates NKG2DL, while 70 
for DNAM-1L it has not been investigated. 71 
IE proteins are the first to be expressed during HCMV lytic infection and play crucial roles in regulating 72 
viral gene expression and in dysregulating host cell physiology, to dictate an intracellular environment 73 
conducive to viral replicative cycle, as well as in counteracting host immune responses (2). The 72-kDa 74 
IE1, 86-kDa IE2 and 55-kDa IE55 proteins share identical N-terminal 85 amino acids resulting from 75 
differentially spliced transcripts, and their expression does not require de novo protein synthesis (18,19). 76 
IE1 and IE2 are absolutely critical for the temporal cascade of viral gene expression, as they transactivate 77 
E and L genes, and either positively or negatively autoregulate their own expression (18,19). While IE1 is 78 
a relatively weak transactivator, IE2 is the most important HCMV regulatory protein and is a strong 79 
transcriptional activator of viral and cellular gene expression. It binds to DNA directly, represses its own 80 
promoter (the Major IE Promoter; MIEP) (20), and cooperates with cellular transcription factors via 81 
protein-protein interactions. These IE2 activities are crucial for transcriptional activation of viral and host 82 
genes, as well as for regulation of several cellular functions (19). The IE55 protein is a splice variant of 83 
IE2 gene product, with a deletion between residues 365 and 519 in the C-terminus, a region required for 84 
many IE2 functions, including transcriptional activation and DNA binding (19,21-25). 85 
Among the cellular pathways activated by IE proteins there is the DNA damage response (DDR) (26,27), 86 
involved in cell-cycle checkpoint control, DNA replication and repair, and apoptosis (28). DDR is 87 
activated by many viruses, including HCMV, and although its functional relevance in HCMV infection 88 
has not been clarified, this virus induces DDR, including activation of ATM, ATR and the downstream 89 
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protein H2AX (26,27,29-34). Interestingly, expression of some NKG2DL and DNAM-1L can be 90 
dependent on the activation of DDR and on ATM/ATR kinases (35-43). 91 
Here, we investigated the role and the mechanisms of IE protein-mediated regulation of NKG2DL and 92 
DNAM-1L, as well as the potential of DDR in stimulating activating ligand expression. This study 93 
provides new mechanistic insight into the regulation of anti-viral immunity by HCMV IE proteins. 94 
95 
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Materials and methods 96 
Antibodies and reagents 97 
The following mAbs were used in flow cytometry: anti-MICA (M673) and anti-ULBP4 (M475) 98 
(Amgen); anti-MICA (AMO-1) (BamOmaB); anti-MICB (MAB236511), anti-ULBP1 (MAB170818), 99 
anti-ULBP2 (MAB165903), and anti-ULBP3 (MAB166510) (R&D Systems); anti-Nectin-2 (CD112) and 100 
mouse control IgG1-Fluorescein isothiocyanate (FITC) (BD Biosciences); anti-PVR (SKII.4) kindly 101 
provided by Dr M. Colonna (Washington University, St Louis, MO); Alexa fluor 488-conjugated anti-IE 102 
antigens (MAB810X) and FITC-conjugated anti-phospho-histone H2AX (γH2AX) (Ser139; clone 103 
JBW301) (Merck Millipore); mouse control IgG (Biolegend); allophycocyanin (APC)-conjugated goat 104 
anti-mouse (GAM) (Jackson Immunoresearch Laboratories); GAM-FITC (Cappel). In cytotoxicity 105 
assays, the following blocking mAbs were used: anti-NKG2D (MAB149810, R&D Systems), anti-106 
DNAM-1 (clone DX11, Bio-Rad), and mouse IgG1 isotype control (Biolegend). The following antibodies 107 
were used in immunoblotting: anti-p85 subunit of PI-3 kinase and anti-IE antigens (MAB810R) (Merck 108 
Millipore); anti-ATM (D2E2) (Cell Signaling Technology); anti-ATR (sc-1887), anti-DNA-PKCS (sc-109 
5282) (Santa Cruz). Other reagents used were: caffeine, methylcellulose, phosphonoformic acid (PFA) 110 
(Foscarnet), gelatin and crystal violet (Sigma Aldrich); Lipofectamine 2000 (Invitrogen), Dharmafect 111 
from Dharmacon (GE Healthcare). The phosphorothioate oligodeoxynucleotide fomivirsen (also known 112 
as ISIS 2922) complementary to IE2 mRNA (44,45) was synthesized by Metabion International AG. 113 
 114 
Cells and culture conditions 115 
Primary human foreskin fibroblasts (HFFs), the retinal epithelial cell line ARPE-19 and the human 116 
embryo kidney 293T cells were purchased from the American Type Culture Collection. HFF and 293T 117 
cells were grown in DMEM containing 10% FCS, 2 mM glutamine, 1 mM sodium pyruvate, 100 U/ml 118 
penicillin, and 100 µg/ml streptomycin sulfate, and ARPE-19 cells in a 1:1 mixture of DMEM and Ham's 119 
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F-12 medium (Invitrogen) containing 10% FCS, 15 mM HEPES, 2 mM glutamine, 1 mM sodium 120 
pyruvate, 100 U/ml penicillin, and 100 μg/ml streptomycin sulfate. HFFs were used at passages 14 to 28. 121 
Human dermal microvascular endothelial cells (HMVECs) (CC-2543) were obtained from Clonetics, and 122 
cultured in endothelial growth medium corresponding to endothelial basal medium (Clonetics), 123 
containing 10% FCS, human recombinant vascular endothelial growth factor, basic fibroblast growth 124 
factor, human epidermal growth factor, insulin growth factor 1, hydrocortisone, ascorbic acid, and 125 
heparin. Cells were seeded onto culture dishes coated with 0.2% gelatin. Experiments were carried out 126 
with cells at passages 4 to 15. Fibroblasts derived from an ataxia-telangectasia mutated patient and not 127 
expressing ATM protein (AT-/-), were kindly provided by Drs. M. Fanciulli and T. Bruno (Regina Elena 128 
National Cancer Institute, Rome, Italy) (46). They were grown in DMEM containing 15% FCS and used 129 
at passages 5 to 8. All cells were maintained at 37°C in a 5% CO2 atmosphere. 130 
 131 
HCMV preparations and infection conditions 132 
The HCMV AD169 strain (ATCC-VR538) was prepared by infecting semi-confluent monolayers of HFF 133 
cells at a virus-to-cell ratio of 0.01, and cultured until a marked cytopatic effect was seen. Stocks were 134 
then prepared after 3 rounds of cell freezing and thawing, subjected to centrifugal clarification, and frozen 135 
at −80°C. Virus titers were measured by standard plaque assays on HFF cells. Stock solutions used in all 136 
experiments contained approximately 2x10
7
 PFU/ml. Standard plaque assays were used also in different 137 
experiments to determine viral titers in the supernatants harvested from infected cells. HCMV TR was 138 
derived from an ocular specimen (47), and after a few passages on fibroblasts, was cloned into a BAC 139 
(48,49). Reconstitution of infectious TR was performed as previously described (50) by co-transfecting 140 
HFFs with the corresponding TR BAC and a plasmid expressing HCMV pp71. Reconstituted infectious 141 
virus retained the ability to infect endothelial and epithelial cells, as well as monocytes and macrophages 142 
(49,50). HCMV VR1814 is a derivative of a clinical isolate recovered from a cervical swab of a pregnant 143 
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woman (51). This strain was propagated in HUVEC and titrated as previously described (52). 144 
Cells were infected at about 80-90% confluence at a molteplicity of infection (MOI) of 1 PFU/cell, unless 145 
otherwise specified, in their respective culture medium, without FCS, and after 2 h (AD169 or TR strains) 146 
or 5 h (VR-1814 strain) at 37°C, virus inoculum was discarded and replaced with fresh growth medium 147 
(day 0). Mock-infected control cultures were exposed for the same amount of time to an equal volume of 148 
medium. At various dpi, cells were harvested and analyzed. In some experiments, PFA was added after 149 
virus inoculation at a final concentration of 200 μg/ml, while fomivirsen was added 1 h before viral 150 
inoculum, maintained in the culture medium during the infection and then throughout the assay (44,45). 151 
The DDR inhibitor caffeine (53,54) was added 2 dpi at a final concentration of 10 mM.  152 
 153 
Adenovirus vectors and infections 154 
Recombinant adenoviruses (AdV) encoding HCMV IE2 (AdV-IE2) and E. coli β-galactosidase (AdV-155 
LacZ) have been previously described (55,56), while AdV-IE72 (AdV-IE1) was kindly provided by Dr. 156 
Timothy F. Kowalik (University of Massachusetts Medical School, Worcester, USA) (27). Recombinant 157 
AdV stocks were generated, purified and titrated as previously described (27,55,56). For adenoviral 158 
transduction, HFFs were infected at about 80-90% confluence at an MOI of 4 PFU/cell in DMEM 159 
without FCS, for 2 h at 37°C. When the viral proteins were not expressed in combination, the total MOI 160 
was equalized to 4 with AdV-LacZ. After 2 h, the virus inoculum was discarded and replaced with fresh 161 
growth medium (day 0) and analyzed at the indicated dpi. Mock-infected cells served as control cultures. 162 
Following infection, cultures were maintained in growth medium and analyzed at the indicated dpi. 163 
 164 
Immunofluorescence and FACS analysis 165 
Mock-infected or infected cells were harvested at the indicated dpi and stained with mAbs specific for 166 
MICA, MICB, ULBP1-4, PVR and Nectin-2, followed by GAM-APC or by GAM-FITC (for experiments 167 
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with PFA), and analyzed by flow cytometry on an FACSCalibur (Becton Dickinson). The mean of 168 
fluorescence intensity (MFI) value of the isotype control antibody was always subtracted from the MFI 169 
relative to each molecule. For intracellular staining of IE antigens or phosho-histone H2AX (γH2AX), 170 
cells were fixed in 1% formaldehyde, permeabilized with 70% ethanol, and then incubated with Alexa 171 
fluor 488-conjugated anti-IE mAb (MAB810X) or with FITC-conjugated anti-γH2AX (JBW301), 172 
respectively. 173 
 174 
Cytotoxicity assays 175 
Cell-mediated cytotoxicity was assessed in 4-h 
51
Cr release assays. Polyclonal NK cells, generated as 176 
previously described (57) were used as effectors, and incubated at different ratios with 5x10
3
 target cells 177 
in U-bottom, 96-well microtiter plates at 37°C in a 5% CO2 atmosphere. To block NKG2D and DNAM-1 178 
receptors, effector cells were preincubated with 1 g/106 cells of specific or isotype control mAbs for 15 179 
min at room temperature. Cells were then washed and used in the assays. Percentage of lysis was 180 
determined by counting an aliquot of supernatant and using the formula: 100 x [(sample release - 181 
spontaneous release)/(total release - spontaneous release)]. Mean inhibition of lysis (%) ± SE by anti-182 
NKG2D, anti-DNAM-1 or isotype control mAb treatment was calculated in comparison to untreated NK 183 
cells (no Ab) using the formula: [1- (% specific lysis by mAb treatment / % specific lysis of no Ab) x 184 
100]. 185 
 186 
Immunoblot analysis 187 
Cells were lysed for 20 minutes at 4°C in a lysis buffer containing 0.2% Triton X-100, 0.3% NP40, 1 mM 188 
EDTA, 50 mM Tris HCl pH 7.6, 150 mM NaCl, and protease inhibitors to obtain whole-cell protein 189 
extracts. Lysates (30-40 µg) were resolved by SDS-PAGE and transferred to nitrocellulose membranes 190 
(Merck Millipore). Membranes were blocked with 5% milk and probed with the indicated antibodies. 191 
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Immunoreactivity was revealed using an enhanced chemiluminescence kit (Amersham). 192 
 193 
siRNA 194 
The ON-TARGETplus SMARTpool siRNA specific for ATM and ATR (siATM, siATR), and the ON-195 
TARGETplus non-targeting pool (siCtrl) were purchased from Dharmacon (Thermo Fisher Scientific). 196 
siRNA specific for DNA-PKCS (sc-35200) (siDNA-PK) was from Santa Cruz. HFFs (70%-80% 197 
confluence) were transfected with 100-200 nM of siRNA using DharmaFECT siRNA Transfection 198 
Reagent (Thermo Fisher Scientific), according to the manufacturer’s recommendations. One to two days 199 
after transfection, cells were infected with AD169, as indicated in the figure legends. Cells and 200 
supernatants were harvested and analyzed at 2 or 3 dpi, as indicated. Densitometric analysis was 201 
performed with ImageJ software. 202 
 203 
RNA isolation and real-time PCR 204 
Total RNA was extracted using TRI Reagent Solution (Life Technologies), according to manufacturer’s 205 
instructions, and 1 µg of total RNA was used for cDNA first-strand synthesis in a reaction volume of 25 206 
µl. Real-Time PCR was performed using the ABI Prism 7900 Sequence Detection system (Applied 207 
Biosystems); cDNAs were amplified in triplicate with primers for MICA (Hs00792195_m1), ULBP3 208 
(Hs00225909_m1), (PVR (Hs00197846_m1), and GAPDH (Hs03929097_g1), using specific TaqMan 209 
Gene Expression Assays (Applied Biosystems). Relative expression of each gene versus GAPDH was 210 
calculated according to the 2
−ΔΔCt
 method. 211 
 212 
Plasmids, transfections and chromatin immunoprecipitation assays (ChIP) 213 
The pGL3-MICA promoter vector was previously described (58) and kindly provided by Dr. J. Bui 214 
(University of California at San Diego, La Jolla, CA). The MICA -270 promoter plasmid was obtained as 215 
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previously described (59). Mutant MICA -270-CG construct was generated using Quick Change Site-216 
Directed Mutagenesis Kit (Stratagene). Primer sequences used were: -92 bp -CGGTCGGGGGACCG -78 217 
bp; primers for mutagenesis: for 5’ -218 
CCAGTTTCATTGGATGAGATGTCGGGGGACATGGCCAGGTGACTAAG-3’; rev 5’-219 
CTTAGTCACCTGGCCATGTCCCCCGACATCTCATCCAATGAAACTGG-3’. Inserted mutations 220 
were verified by sequencing. pGL2-PVR (-571 bp fragment) promoter luciferase reporter vector and 221 
progressive deletions were kindly provided by Dr. G. Bernhardt (Hannover Medical School, Hannover, 222 
Germany) (60). pSG5-IE1, pSG5-IE2, and pSG5-IE55 were previously described (24). The IE2 cDNA 223 
cloned in the pRSV vector and the zinc finger mutant of IE2, with cysteines 428 and 434 mutated into 224 
serine residues (pRSV-IE2-Zn mut), were a generous gift of Prof. Jay Nelson (61). 225 
In all transfection experiments, 3 µg of luciferase reporter, 0.25 μg of pRL-CMV-Renilla, and 2 μg of IE 226 
protein vectors or pSG5 empty vector were co-transfected into 80-90% confluent cells growing on a 10 227 
cm
2
 area using Lipofectamine 2000 (Invitrogen) according to the manufacturer’s protocols. In some 228 
experiments, the pSG5-IE2 vector was replaced by pSG5-IE55, pRSV-IE2 or pRSV-IE2-Zn-mut, as 229 
indicated. 48 h post-transfection, cells were harvested and prepared for the luciferase assays, using the 230 
Dual-Luciferase Reporter Assay kit and the Glomax Multi Detection System (Promega), following the 231 
manufacturer’s instructions. Relative luciferase activity was calculated by dividing the luciferase activity 232 
of pGL3-MICA or pGL2-PVR reporter, co-transfected with IE proteins, by the respective pGL3- or pGL2-233 
Basic, to remove the unspecific effect of IE proteins on the reporter vector. The unspecific modulation of 234 
the reporter empty vector activity was probably due to a general activation of the transcriptional 235 
machinery by IE proteins, and was more evident for IE1. This correction allowed us to better appreciate 236 
the specific effect of the viral proteins on ligand promoters. 237 
In ChIP assays, 293T cells were co-transfected with 5 µg of MICA -270 promoter plasmid, wild-type or 238 
mutated, and pSG5-IE1 (10 µg) and pSG5-IE2 (10 µg), or pSG5 empty vector (20 µg), using 239 
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Lipofectamine 2000. In ChIP assays on the endogenous MICA promoter, 293T cells were transfected with 240 
pSG5-IE1, pSG5-IE2, or pSG5 empty vector. After 48 h, cells were processed for ChIP assays following 241 
the manufacturer’s protocol of Magna ChIP AG chromatin immunoprecipitation kit (Merck Millipore). 242 
Chromatin was immunoprecipitated with a polyclonal rabbit anti-IE antibody, recognizing a segment of 243 
IE2 (amino acids 1-143), or control polyclonal rabbit serum. PCR primers used were: MICA for 5′-244 
AGGTCTCCAGCCCACTGGAATTTTCTC-3′; MICA rev 5′-CGCCACCCTCTCAGCGGCTCAAGC-245 
3′. Results are expressed as relative enrichment as compared to the input. Negative control (polyclonal 246 
rabbit serum) values were subtracted from the corresponding samples. Quantifications were obtained by 247 
serial dilutions of the input DNA samples. The analysis was performed using the SDS version 2.4 248 
software (Applied Biosystems). PCRs were validated by the presence of a single peak in the melt curve 249 
analysis, and amplification of a single specific product was further confirmed by electrophoresis on 250 
agarose gel. 251 
 252 
Confocal microscopy analysis 253 
For staining of cell surface MICA, HFFs were grown to semi-confluence on glass coverslips in 24-well 254 
plates and infected with AD169 and TR at a MOI of 1 PFU/cell for 2 h at 37°C. After 4 dpi, cells were 255 
washed with PBS, fixed in 1% paraformaldehyde for 15 min at room-temperature (RT), blocked in 1% 256 
FCS diluted in PBS (20 min., RT), but not permeabilized. Indirect immunofluorescence analysis was 257 
performed by incubating fixed cells with the anti-MICA mAb AMO-1 (1:40) for 2 h at 37°C, followed by 258 
secondary antibody incubation with CF594-conjugated rabbit anti-mouse IgG (Sigma) for 1 h at RT. 259 
Samples were then visualized with an Olympus IX70 inverted laser scanning confocal microscope, and 260 
images were captured using FluoView 300 software (Olympus Biosytems). 261 
Statistical analysis 262 
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Statistical analysis of the data was performed using a paired Student t-test, or a one-way analysis of 263 
variance (ANOVA), where indicated. *: p<0.05; **: p<0.01; ***: p<0.001; ****: p<0.0001. 264 
265 
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Results 266 
Regulation of NKG2D and DNAM-1 ligand expression by different HCMV strains. 267 
Increased or de novo expression of T/NK cell activating ligands on infected cells represents a crucial host 268 
immune defense mechanism to sense and react against different pathogens (7,12). Therefore, we 269 
examined the expression of NKG2DL and DNAM-1L in several cell models with multiple HCMV 270 
strains. Firstly, human primary foreskin fibroblasts (HFFs) were infected with the HCMV laboratory 271 
strain AD169. We observed higher levels of MICA and ULBP3 on infected HFFs, with maximal 272 
expression around 3 dpi, whereas no changes in MICB, ULBP1 or ULBP4 expression were detected. In 273 
contrast, ULBP2 was down-modulated by HCMV (Figure 1). The DNAM-1L PVR, but not Nectin-2, was 274 
also up-regulated by HCMV, with a maximal increase at 3 dpi (Figure 1). 275 
To verify that the augmented expression of MICA, ULBP3 and PVR was not restricted to a particular 276 
viral strain, their modulation was also examined in HFFs infected with the low-passage strains VR-1814 277 
and TR. Consistently, an induction of MICA was observed upon infection with VR-1814, independently 278 
of the MOI (Fig. 2A-B). Low, but statistically significant level of MICA induction was also observed 279 
with TR (Fig. 2C), and was confirmed by confocal microscopy (Fig. S1). ULBP3 and PVR ligands were 280 
also up-regulated on HFFs infected with VR-1814 (Fig. 2A-B) or TR (Fig. 2C). Taken together, these 281 
results demonstrated that by 3-4 dpi, MICA, ULBP3 and PVR were up-regulated on infected primary 282 
fibroblasts in a HCMV strain-independent manner. 283 
Next, we extended our investigation to other cell type-viral strain combinations, by infecting primary 284 
endothelial (HMVEC) and epithelial cells (ARPE-19) with TR and VR-1814 strains (Figure 2C). MICA 285 
expression was either down-modulated on TR-infected HMVECs, or not affected in the other 286 
combinations, while ULBP3 and PVR were always up-regulated, independently of the cell type and/or the 287 
viral strain used. 288 
Thus, these results demonstrate that, despite few exceptions, HCMV positively regulates the expression 289 
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of MICA, ULBP3 and PVR activating ligands, with a pattern that generally overcome cellular- or viral 290 
strain-related differences. 291 
 292 
NKG2D and DNAM-1 ligands contribute to the NK cell-mediated killing of infected fibroblasts. 293 
Next, we tested whether the observed upregulation of NKG2D and DNAM-1 ligands upon HCMV 294 
infection had consequences on NK cell-mediated cytotoxicity. Chromium-release assays were performed 295 
using polyclonal NK cell cultures from different donors as effectors, and uninfected or AD169- and TR-296 
infected HFFs as targets. HFFs infected with the low-passage strain TR became more resistant to NK 297 
cell-mediated lysis, while infection with AD169 resulted in a variable pattern, with an either increased, 298 
unchanged or decreased sensitivity (Fig. 3A and data not shown). These results are in line with previous 299 
observations on both laboratory and low-passage HCMV strains, which demonstrated that cells infected 300 
with low-passage strains were more resistant to NK cell-mediated cytotoxicity, compared to AD169-301 
infected cells (14,15,57,62). Nevertheless, despite the increased resistance of TR-infected cells to NK  302 
cell lysis, blocking NKG2D or DNAM-1 receptors resulted in a significant inhibition, that was 303 
comparable to that observed with AD169-infected cells or uninfected cells, in all experiments performed 304 
(Fig. 3B).  305 
Overall, these data indicate that NKG2D and DNAM-1 receptors contribute to the elimination of HCMV-306 
infected cells. Moreover, despite the increased resistance to NK lysis of HFFs infected with the TR strain, 307 
NKG2D and DNAM-1 ligands still contribute to the recognition of these target cells, in accordance with 308 
the increased expression of MICA, ULBP3 and PVR ligands upon TR infection. 309 
  310 
Role of the DDR and of ATM, ATR and DNA-PK on HCMV-induced ligand up-regulation. 311 
As previous studies reported that HCMV manipulates the DDR (26,27,29-34), a pathway able to 312 
stimulate NKG2DL and DNAM-1L expression as well (35-43), we examined the involvement of DDR 313 
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signaling in the HCMV-mediated up-regulation of activating ligands, using genetic and pharmacological 314 
approaches. 315 
Upon HCMV infection, the levels of γH2AX, the phosphorylated form of the histone variant H2AX, a 316 
well-known substrate of DDR kinases (28), increased of approximately two-fold, demonstrating 317 
activation of the DDR pathway in our experimental settings (Fig. S2A-B). Next, we determined the 318 
contribution of the three main DDR kinases (ATM, ATR and DNA-PK) on ligand expression, IE 319 
expression and viral replication. Firstly, the role of ATM was investigated in fibroblasts derived from a 320 
patient affected by ataxia-telangiectasia (AT-/-), where ATM is not detectable. HCMV infection still 321 
increased the expression of MICA, ULBP3 and PVR, though with delayed kinetics compared to normal 322 
HFFs (Fig. S2C). Moreover, both progeny virus production and IE expression were only partially affected 323 
in AT-/- cells, but not in a statistically significant manner (data not shown). Then, we used specific 324 
siRNA to transiently deplete ATM (siATM) (Fig. S2D-G), and consistently to AT-/- fibroblasts, there 325 
was no effect on MICA, ULBP3 and PVR expression induced by HCMV (Fig. S2D), and on the 326 
percentage of IE+ cells and viral replication (Fig. S2E-F). Similar results were obtained with siRNA 327 
specific for ATR (Fig. S3A-D) or DNA-PK (Fig. S3E-H), as well as with a triple gene silencing with the 328 
three siRNA specific for ATM, ATR and DNA-PK (siDDR) (Fig. 4). Finally, activating ligands were still 329 
up-regulated in AD169-infected HFFs treated with caffeine, a well-known and broad spectrum inhibitor 330 
of DDR (data not shown). 331 
Altogether, these results suggest that DDR activation does not play a role in the HCMV-induced up-332 
regulation of MICA, ULBP3 and PVR. 333 
 334 
The HCMV-induced ligand increase depends on events occurring prior to the onset of viral DNA 335 
replication and involves transcriptional activation. 336 
To identify the molecular mechanisms underlying ligand up-regulation in HCMV-infected cells, we 337 
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hypothesized that some events in the early stages of infection could be responsible. To verify this 338 
hypothesis, HFFs were infected with HCMV and treated with phosphonoformic acid (PFA), a selective 339 
inhibitor of viral DNA polymerase (63). As shown in Fig. 5, MICA, ULBP3 and PVR levels were 340 
increased on the surface of infected cells even in the presence of PFA, indicating that viral DNA 341 
replication and expression of delayed-E and L genes are dispensable for ligand up-regulation. 342 
Next, to investigate whether the increase in ligand cell surface levels was a consequence of a virus-343 
induced transcriptional activation, we measured ligand mRNA content by real-time PCR at different 344 
hours post-infection (hpi). MICA, ULBP3 and PVR mRNA progressively increased during the course of 345 
infection, with a maximal expression at 24-48 hpi (Fig. 6). 346 
These data suggest that up-regulation of MICA, ULBP3 and PVR cell surface levels by HCMV is the 347 
outcome of a transcriptional activation of the corresponding genes. 348 
 349 
HCMV IE proteins up-regulate MICA and PVR gene expression. 350 
Because early steps of infection were crucial for ligand up-regulation, we investigated if the major viral 351 
IE proteins, IE1 and IE2, were involved in the modulation of MICA, ULBP3 and PVR expression, by 352 
transducing HFFs with recombinant adenoviruses (AdV) encoding for IE1, IE2, or their combination, and 353 
analyzing ligand mRNA and cell surface levels at 24, 48 and 72 hpi. There was a significant up-354 
regulation of MICA mRNA at all time points only in IE2 transduced cells, while IE1 did not affect MICA 355 
mRNA levels, neither when used alone nor in combination with IE2 (Fig. 7A). Similar results were 356 
obtained for MICA cell surface expression, which showed an IE2-dependent increase, particularly evident 357 
at 72 hpi (Fig. 7B-C and data not shown). In contrast, PVR mRNA content and membrane expression was 358 
mostly up-regulated by the co-expression of IE1 and IE2, while IE proteins alone had weaker effect (Fig. 359 
7A-C). ULBP3 mRNA and cell surface expression were instead not affected by IE proteins (Fig. S4). 360 
Thus, while the HCMV-induced up-regulation of ULBP3 may be the consequence of other virus-related 361 
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effects than the solely overexpression of IE1/IE2, MICA and PVR increase could be reproduced by 362 
expression of IE proteins, though with different requirement.  363 
Then, to further sustain the role of IE proteins in MICA an PVR up-regulation, we inhibited their 364 
expression by using fomivirsen (also known as ISIS 2922), an antisense oligodeoxynucleotide 365 
complementary to IE2 mRNA, and able to prevent both IE1 and IE2 protein expression when used at 366 
certain concentration (44,45). This approach allowed us to specifically address the role of IE proteins in 367 
regulating ligand expression within the context of HCMV infection. To this end, HFFs were treated with 368 
different doses of fomivirsen, from 1 h before and throughout the entire infection (Fig. 8). At the highest 369 
dose of fomivirsen (500 nM), expression of both IE1 and IE2 was inhibited (Fig. 8C-D) as previously 370 
observed by Azad et al. (44) and, as expected, MICA and PVR up-regulation could not be detected (Fig. 371 
8A-B). By progressively decreasing the concentration of fomivirsen (to 5 and 1 nM), we could rescue  372 
IE1 protein expression (which was the first IE protein to reappear), and IE2 (Fig. 8C-D). At these low 373 
concentrations of fomivirsen, recovery in HCMV-induced ligand up-regulation was observed (Fig. 8A-374 
B).  375 
These results clearly demonstrated that the specific inhibition of IE protein expression in the context of 376 
HCMV infection prevented MICA and PVR increase, therefore supporting the importance of these viral 377 
proteins in the HCMV-mediated ligand regulation.  378 
Next, we further examined the possibility that IE proteins could activate MICA and PVR gene promoters. 379 
Thus, we co-transfected HFFs with pGL3-MICA (58) or pGL2-PVR (60) luciferase reporter plasmids, 380 
harboring respectively -1 kb and -571 bp MICA and PVR promoter regions, together with IE1 or IE2 381 
expression vectors. We observed that only IE2 transactivated MICA promoter, up to ~3-fold compared to 382 
the control. Transfection of IE1, alone or together with IE2, did not significantly affect MICA promoter 383 
activity, compared to IE2 alone (Fig. 9A). These results are in line with previous observations obtained 384 
on the regulation of MICA mRNA and cell surface expression in cells transduced with AdV IE2.  385 
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We then analyzed IE2 structural requirements and its interaction with MICA promoter sequences. Firstly, 386 
we observed that expression of IE55, which lacks the transcriptional activation and DNA binding 387 
properties of IE2, was a poor transactivator of MICA, either in combination with IE1 (Fig. 9B), or alone 388 
(Fig. 9D). Then, a zinc finger mutant of IE2, which cannot bind to DNA but retains the ability to 389 
transactivate E gene promoters by protein-protein interactions (61,64), did not significantly increase 390 
MICA promoter activity, neither with IE1, nor alone (Fig. 9C and E). These results indicate that the IE2 391 
functional domains located primarily toward the C-terminal end of the protein are required to 392 
transactivate MICA gene promoter. 393 
Then, we used a shorter MICA construct (MICA -270 bp) to map the region(s) targeted by IE proteins. 394 
This fragment was indeed activated by IE1 and IE2 at similar levels compared to the longer MICA -1 kb 395 
region, indicating that the IE-responsive region was contained within the 270 bp fragment (Fig. 10A). 396 
IE2-binding sites identified on viral and cellular promoters contain invariant CG residues at both ends of 397 
a 10-nucleotide sequence (CG-N10-CG) (20,25,65,66), and we found a similar sequence within MICA 398 
promoter, between residues –92 and –78 (Fig. 10B). To evaluate the contribution of this putative IE2-399 
binding site to the overall IE2-dependent transactivation of MICA, we changed by site-directed 400 
mutagenesis this unique CG-N10-CG motif into a AT-N10-AT sequence within the context of the MICA -401 
270 construct. The introduced mutations significantly reduced IE2-dependent transactivation of MICA, 402 
thus supporting an involvement of the putative IE2-binding site in the regulation of this promoter (Fig. 403 
10A-B). 404 
We then addressed the capability of IE1/IE2 proteins to directly bind to MICA promoter by ChIP assays, 405 
using the wild-type or the CG-mutant form of MICA, in highly transfectable 293T cells. Using an anti-IE 406 
antibody and specific primers to amplify the region containing the putative IE2 binding site, we observed 407 
that IE1/IE2 were recruited to MICA promoter. The interaction was not detectable with the empty vector 408 
pSG5 or using normal rabbit serum as a negative control (Fig. 10C). Disruption of the putative IE2-409 
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binding site of MICA reduced IE binding of about ~60%, further demonstrating that this sequence is 410 
involved in the IE2-dependent transactivation of MICA (Fig. 10D). The binding was confirmed on the 411 
endogenous MICA promoter as well, and it was detectable only when IE2 was expressed (Fig. 10E). 412 
Together, these results demonstrate the capability of IE2 to directly bind sequences within MICA gene 413 
promoter, and that this binding is required for MICA transcriptional activation. 414 
In relation to PVR, we performed similar transient cotransfection assays with a PVR -571 bp construct 415 
(60) and vectors expressing IE proteins. Though IE1 activated PVR promoter up to 10-fold over the 416 
control, the combination of IE1 and IE2 induced a prominent transcriptional activation that exceeded 417 
significantly the effect of IE1 alone. IE2 was instead ineffective in stimulating PVR (Fig. 11A). In 418 
contrast to what observed for MICA, expression of IE55 and of IE2 zinc finger mutant did not affect PVR 419 
promoter activity (Fig. 11B-C). Finally, to identify the IE-responsive region(s), we cotransfected IE1 and 420 
IE2, alone or in combination, with progressive deletions of PVR promoter (Fig. 11D-E) (60), and 421 
observed a significant drop in luciferase activity with the truncated sequences between -281 and -213 bp, 422 
indicating that this fragment mediated most of the transactivating activity resulting from the combination 423 
of IE1 and IE2, and only in minor part from IE1 alone (Fig. 11E).  424 
Taken together, the results of this section indicate that the increase in cell surface expression of MICA 425 
and PVR upon HCMV infection is mediated by IE proteins through the transcriptional activation of their 426 
gene promoters. 427 
428 
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Discussion 429 
The molecular mechanisms driving the expression of NKG2DL and DNAM-1L remain largely unknown, 430 
particularly in virus-infected cells. In this study, we investigated the impact of HCMV infection on their 431 
expression and showed that MICA, ULBP3 and PVR are up-regulated on infected cells, in different cell 432 
type-viral strain combinations. For MICA, data suggest that its increased or de novo expression may be 433 
restricted to certain cell types, as it was observed on infected fibroblasts independently from the strain 434 
used, but not in endothelial or epithelial cells. Information on a cell-type specific regulation of MICA 435 
expression are currently not available, and further investigations would be of unquestionable interest for a 436 
better characterization of this molecule. However, the evidence that in primary fibroblasts MICA was 437 
induced by both laboratory and low-passage HCMV strains suggests that the down-modulating activity 438 
exerted by the viral proteins UL142, US9, US18 and US20 on this ligand (14-17) was not sufficient to 439 
prevent its overall cell surface expression. Similarly, though UL142 was described to prevent expression 440 
of ULBP3 as well (67), in our settings this ligand was always increased, consistently with previous 441 
findings (57). These discrepancies may be related to different experimental conditions and/or to the 442 
considerable polymorphism in the UL142 sequence among different strains (68,69). Thus, some variants 443 
of viral proteins may be less efficient at down-modulating NKG2DLs than others. At the same time, 444 
polymorphisms in both the coding and non-coding regions of MICA and ULBP3 (70-73) may also impact 445 
their expression upon HCMV infection. Thus, a prediction deriving from the presence of NKG2DL on the 446 
cell surface of HCMV-infected targets would be that blocking the receptor in cytotoxicity assays results 447 
in a decreased NK cell lysis. Indeed, this was the outcome of blocking experiments (Fig. 3), which 448 
demonstrated that the NKG2D receptor plays a role in the elimination of infected cells, as previously 449 
shown (57). 450 
In relation to PVR, at present there are few reports on its regulation by HCMV (74-76). In particular, its 451 
expression resulted down-modulated in fibroblasts infected with the low-passage strain Merlin (74,75). In 452 
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contrast, our results show for the first time that PVR can be up-regulated by HCMV infection, in different 453 
cell types and with different viral strains, thus offering the immune system the opportunity to detect and 454 
react against infected cells through the activating receptor DNAM-1. Indeed, blocking of DNAM-1 in 455 
killing assays resulted in a significant inhibition of target cell lysis, similarly to what we observed for 456 
NKG2D (Fig. 3). Thus, from a functional point of view, the numerous HCMV immunoevasion strategies 457 
evolved against NKG2D and DNAM-1 ligands seems to be not completely successful, since these 458 
activating receptors still play a role in eliminating infected cells, including those infected with low-459 
passage strains, which are per se less susceptible to NK killing (this study and ref.(14,15,57,62). In line 460 
with our data, DNAM-1 plays a relevant role in NK cell recognition of HCMV-infected myeloid dendritic 461 
cells early in infection, whereas the effect of viral-mediated down-regulation of DNAM-1L prevails at 462 
later stages, thus underlying the importance of the kinetics of immune evasion mechanisms (76). 463 
Moreover, a recent study demonstrated that DNAM-1L are rapidly induced during murine CMV infection 464 
in vivo, and the engagement of DNAM-1 is essential for the optimal NK cell-mediated host defense 465 
against the virus (11). Of note, as DNAM-1 is also expressed by many other leukocyte subsets and is an 466 
important activator of their effector functions, it may impact on a wide range of immunological responses 467 
(8,12,13,77).  468 
To gain insights into the molecular mechanisms regulating the expression of activating ligands in infected 469 
cells, we investigated the role of DDR, a host cell pathway that positively affects the expression of 470 
activating ligands (35-43), and that it is activated by HCMV (26,27,29-34). Nevertheless, in HCMV-471 
infected HFFs, MICA, ULBP3, and PVR were still increased even if ATM, ATR, and/or DNA-PK were 472 
knocked-down, thus indicating that these DDR kinases are not involved in the HCMV-mediated ligand 473 
stimulation, similarly to what has been reported for murine NKG2DL during murine CMV infection (78). 474 
HCMV IE proteins have been suggested to be implicated in the regulation of MIC proteins (16,79), but 475 
the molecular mechanism(s) are unknown. Moreover, no data have been reported on the regulation of 476 
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PVR by HCMV. Our results show that ectopic expression of IE1 and IE2 induced a significant increase of 477 
MICA and PVR, both at the mRNA and cell surface level. In particular, IE2 emerged as the main 478 
transactivator of MICA promoter, with the effect strictly dependent on its DNA binding activity, since it 479 
was lost in the presence of the IE55 isoform or the zinc finger mutant form of IE2. Accordingly, through 480 
ChIP and mutagenesis approaches, we identified an IE2 consensus sequence within the MICA gene 481 
promoter that turned out to be critical for MICA promoter transactivation by IE2. 482 
This observation contributes to challenge the prevailing view that activation of cellular genes by IE2 483 
depends from interactions with basal transcription factors, while nucleotide-specific binding of IE2 is the 484 
predominant mode of regulation of HCMV promoters (19-21,25,65). Moreover, this finding also suggests 485 
that the IE2-binding sites on cellular versus HCMV promoters are different, with the 10-internal 486 
nucleotides of the CG-N10-CG motifs being GC-rich, rather than AT-rich, as previously suggested for the 487 
cyclin E promoter (66), and support the idea that IE2 is relatively sequence tolerant (25,65,66). 488 
In regard to PVR, our results demonstrate a different mechanism of the HCMV-induced up-regulation. In 489 
fact, PVR mRNA and protein up-regulation required the co-expression of both IE1 and IE2. Furthermore, 490 
by using progressive deletions of PVR promoter, we mapped a region between -281 bp and -213 bp 491 
mostly responsive to IE1/IE2 combination. This fragment contains a potential IE2-responsive CG-N10-CG 492 
element (from -271 to -257: CG-CAGGCGCAGG-CG), but it is unlikely that IE1/IE2 proteins bind to 493 
PVR promoter since the IE55 isoform and the zinc finger mutant of IE2 retained the capability to activate 494 
PVR promoter, and IE1 seems not to bind DNA directly (18). Accordingly, in ChIP assays we were 495 
unable to observe any detectable binding to the PVR promoter neither of the single IE proteins, nor of 496 
their combination (data not shown). Thus, it is more likely that the -281/-213 bp region contains the 497 
binding site(s) of cellular transcription factor(s) recruited and/or activated by IE proteins. In fact, this 68 498 
bp region contains putative binding sites for several transcription factors, such as E2F, Sp1, AP-2, Nrf-499 
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1, and NF-kB (Fionda et al., unpublished observations), but further studies should be undertaken to 500 
identify which are the cellular proteins involved in the IE-mediated activation of PVR promoter. 501 
As a final consideration on the importance of IE proteins in the regulation of MICA and PVR gene 502 
expression, we should also underline that it was observed not only by IE overexpression, but also in the 503 
context of HCMV infection. Indeed, by using fomivirsen (44,45), we observed that the inhibition of IE 504 
protein expression prevented the HCMV-induced MICA and PVR up-regulation (Fig. 8). Conversely, 505 
regaining IE protein expression by lower doses of fomivirsen, resulted in a recovery of ligand 506 
upregulation as well. These data thus clearly demonstrate that inhibition of IE protein expression in 507 
HCMV-infected cells prevents MICA and PVR increase. 508 
In regard to ULBP3 regulation, though we could detect a significant increase in its mRNA and cell 509 
surface level upon HMCV infection, overexpressing IE1/IE2 by adenoviral vectors did not have a major 510 
effect on the expression of this ligand (Fig. S4), suggesting that IE1/IE2 were not sufficient for ULBP3 511 
up-regulation. 512 
From our study, two questions arise: the first one is why a virus should increase the expression of 513 
molecules involved in the elimination of infected cells? A possible answer could derive from the absolute  514 
requirement of IE proteins for a productive viral replication (18,19), with the induction of NKG2DL and 515 
DNAM-1L being an unavoidable side effect of the strong transactivating activity of IE2. In this scenario, 516 
up-regulation of activating ligands in HCMV-infected cells may represent an acceptable toll to pay to 517 
survive. Moreover, the IE2-consensus sequence we identified is conserved among different allelic 518 
variants of MICA promoter (Fionda et al., unpublished observations, and ref. (72,73), suggesting that 519 
during the virus-host co-evolution, a positive selection of promoter sequences in MICA alleles carrying 520 
the IE2 DNA binding site occurred, with the host likely making IE2 useful for its own cellular gene 521 
expression as well. The second question is how can we reconcile the observed HMCV-triggered increase 522 
of activating ligands with the immunoevasion strategies evolved by the virus to target the same 523 
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molecules? There could be a window of opportunity, a temporal frame in the early phases of HMCV 524 
infection, during which the unavoidable up-regulation of NKG2DL and DNAM-1L by IE proteins 525 
precedes the late expression of virus-encoded immunoevasion proteins. Thus, with elevated, functionally 526 
relevant levels of activating signals, the immune surveillance against the viral infection could be 527 
sufficiently robust, allowing recognition of infected cells by cytotoxic lymphocytes even at early times of 528 
infection. Moreover, HMCV diversity and tropism could have an important role as well. In fact, a 529 
hallmark of HCMV infections is its dissemination to a wide range of host tissues and cell types (3) with 530 
significant differences in the level of virus diversity between different compartments (80,81). Although it 531 
is not yet clear neither the mechanism explaining HCMV compartmentalization and intrahost genetic 532 
diversity, nor their effects on clinical disease, one possibility is that the generation of mutants may 533 
influence NK cell and/or T cell recognition, depending on the compartment (81). 534 
In conclusion, our findings contribute to improve the understanding of the mechanisms underlying the 535 
regulation of the expression of NKG2D and DNAM-1 ligands, and consequently affecting immune 536 
responses mediated by their activating receptors expressed on all cytotoxic lymphocytes. This knowledge 537 
may be exploited to take full advantage of this potent immune pathway for therapeutic purposes. 538 
539 
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Figure legends 806 
Figure 1. NKG2D and DNAM-1 ligand expression on AD169-infected fibroblasts. HFFs were 807 
infected with HCMV AD169 (MOI 1 PFU/cell) or mock-infected (n.i.) and harvested at different days 808 
post-infection (dpi). Ligand expression was evaluated by FACS. A) A representative experiment of at 809 
least four performed at 3 dpi is shown. Dashed lines indicate isotypic control IgG on n.i. or infected cells. 810 
B) The kinetics of ligands with an increased expression upon HCMV infection is shown. Expression 811 
levels are presented as mean of fluorescence intensity (MFI). Data from at least four independent 812 
experiments ± SEs. 813 
 814 
Figure 2. NKG2D and DNAM-1 ligands are up-regulated on different cell types by HCMV low-815 
passage strains VR-1814 and TR. HFFs, HMVEC or ARPE-19 cells were mock-infected (n.i.) or 816 
infected with the indicated HCMV low-passage strain, and harvested at 3 dpi. A) A representative 817 
experiment of HFFs infected with the low-passage strain VR-1814, and with AD169 as a control, is 818 
shown. B) HFFs were infected with VR-1814 (MOI 1 and 5 PFU/cell). Data from three experiments ± 819 
SEs. C) HFFs, HMVEC, and ARPE-19 cells were infected with TR or VR-1814 (MOI 1 PFU/cell). Data 820 
from three or five (HFFs with TR) experiments ± SEs. Expression levels are presented as MFI.  821 
 822 
Figure 3. Contribution of NKG2D and DNAM-1 to NK cell-mediated cytotoxicity against mock-infected 823 
(n.i.), AD169- or TR-infected HFFs (MOI 1, 3 dpi). A) A representative 4 h chromium-release assay in 824 
which effector cells were left untreated (no Ab), or were preincubated with anti-NKG2D, anti-DNAM-1, 825 
or IgG1 isotype control mAb, is shown. B) Reduction of NK cell-mediated killing of n.i., AD169- or TR-826 
infected HFFs by mAb treatment (pooled data from four experiments with NK cells obtained from 827 
different donors, at 50:1). Mean inhibition of lysis (%) was calculated in comparison to untreated NK 828 
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cells (no Ab), and statistical analysis was performed with ANOVA, as described in Materials and 829 
Methods.  830 
 831 
Figure 4. Triple silencing of ATM, ATR and DNA-PK does not affect MICA, ULBP3 and PVR 832 
expression. HFFs were firstly transfected with DNA-PK siRNA or with a non-targeting siRNA (siCtrl). 833 
24 h later, the same cells were co-transfected with ATM and ATR siRNA, or with siCtrl. Then, 24 h later, 834 
cells were either mock-infected (n.i.) or infected with AD169 (MOI 1 PFU/cell); then, at 3 dpi cells and 835 
supernatants were harvested. A) FACS of MICA, ULBP3 and PVR expression, derived from three 836 
experiments, with expression levels presented as MFI ± SEs. B) The % of IE+ cells was analyzed by 837 
FACS on HCMV-infected cells stained intracellularly with a specific anti-IE mAb. C) Cell culture 838 
supernatants were assayed for infectious virus production by plaque assay. D) Levels of ATM, ATR and 839 
DNA-PK protein expression were assayed by immunoblot analysis with specific antibodies. The p85 840 
subunit of PI-3K was used as loading control. One representative experiment out of three is shown. E) 841 
The amounts of ATM, ATR and DNA-PK, normalized to that of p85, were determined by densitometric 842 
analysis and are relative to that in n.i./siRNA Ctrl cells, which was arbitrarily set as 1. Data are expressed 843 
as mean ± SEs of three independent experiments. ns: not statistically significant difference. siDDR: cells 844 
transfected with siATM, siATR and siDNA-PK. 845 
 846 
Figure 5. Immediate early and early genes, but not late genes, are per se sufficient to increase the 847 
expression of MICA, ULBP3 and PVR in infected cells. HFFs were infected with HCMV AD169 848 
(MOI 1 PFU/cell) or mock-infected (n.i.), and then treated with 200 µg/ml of phoshonoformic acid (PFA) 849 
immediately after infection. At 3 dpi, cells were harvested and stained for MICA, ULBP3, PVR or 850 
isotype control IgG, followed by GAM-FITC. Top panels: one representative experiment out of four is 851 
shown. Bottom panels: data are represented as MFI ± SEs of four independent experiments. 852 
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 853 
Figure 6. Up-regulation of MICA, ULBP3 and PVR mRNA in HCMV-infected cells. HFFs were 854 
infected with HCMV AD169 (MOI 1 PFU/cell) or mock-infected (n.i.). At the indicated times post-855 
infection, total RNA was isolated and reverse transcribed. cDNAs were amplified by real-time PCR using 856 
primers specific for MICA, ULBP3, PVR, or GAPDH. Data from four experiments, expressed as fold 857 
change units ± SEs, were normalized with GAPDH and referred to n.i. cells considered as calibrators, and 858 
set at 1.  859 
 860 
Figure 7. Adenoviral-mediated overexpression of IE1 and IE2 proteins increases mRNA and cell 861 
surface expression of MICA and PVR. HFFs were transduced with adenoviral vectors (AdV) 862 
expressing IE1, IE2, or LacZ as a control, alone or in combination (total MOI 4 PFU/cell). Cells were 863 
harvested 24 h, 48 h or 72 h later, and analyzed for ligand mRNA and surface expression. A) Real-time 864 
PCR for MICA and PVR. Data from four experiments ± SEs, expressed as fold change units, were 865 
normalized with GAPDH and referred to not-transduced cells (-), considered as calibrators and set at 1. 866 
B) FACS of MICA and PVR expression, derived from three experiments at 72 hpi, with expression levels 867 
presented as MFI ± SEs. C) MICA and PVR cell surface expression from a representative experiment 868 
performed at 72 hpi. Statistical analysis was performed with ANOVA. 869 
 870 
Figure 8. MICA and PVR up-regulation during HCMV infection is inhibited in the presence of 871 
fomivirsen. HFFs were treated or not with the indicated dose of fomivirsen 1 h before, and then during 872 
the infection with HCMV AD169 (MOI 1 PFU/cell). The drug was maintained in the culture medium 873 
until cell harvesting and processing, at 3 dpi. A, B) FACS of MICA and PVR expression, derived from 874 
four experiments, with expression levels presented as MFI ± SEs. C) Levels of IE1 and IE2 protein 875 
expression were assayed by immunoblot analysis with anti-IE mAb. The p85 subunit of PI-3K was used 876 
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as loading control. One representative experiment out of four is shown. D) The amounts of IE proteins, 877 
normalized to that of p85, were determined by densitometric analysis and are relative to that in HCMV 878 
infected cells without fomivirsen, which was arbitrarily set as 1. Data are expressed as mean ± SEs of 879 
four independent experiments. Statistical analysis was performed with ANOVA. 880 
 881 
Figure 9. IE2 activates MICA promoter: role of the DNA binding activity. A) HFFs were transfected 882 
with pGL3-MICA (-1 Kb fragment) luciferase reporter plasmid, together with IE1 and/or IE2 expression 883 
vectors, or with the empty control vector pSG5. After 48 h, transfected cells were harvested and protein 884 
extracts were used for luciferase assay. Luciferase activity was calculated as described in Materials & 885 
Methods, and results are expressed as fold-induction compared to pSG5. B) and C) IE2-86 was replaced 886 
by IE2-55 (B) or by a zinc finger domain mutant of IE2-86 (IE2-Zn mut) (C). In panels D) and E) MICA 887 
promoter activation induced by IE2-55 (D) or IE2-Zn mut (E) alone is shown. Data from at least three 888 
experiments ± SEs.  889 
 890 
Figure 10. Identification of an IE2 consensus site in MICA promoter. A) HFFs were transfected with 891 
wild-type (wt) pGL3-MICA (-270 bp fragment) promoter luciferase reporter vector, or with a mutated 892 
form (CG-mut), together with IE expression vectors, or pSG5. After 48 h, cells were harvested and 893 
luciferase activity was calculated as described in figure 9. Data from three experiments ± SEs. B) the CG-894 
N10-CG sequence identified on MICA promoter, and its mutated form (CG-mut), are reported and 895 
compared with some of the IE2-binding sites described on the HCMV MIEP, the 2.2 Kb early promoter 896 
and the cyclin E promoter. C) 293T cells were co-transfected with wt pGL3-MICA (-270 bp fragment) 897 
promoter, and IE expression vectors or pSG5. After 48 h, cells were harvested and processed for ChIP 898 
assays. Results are shown as relative enrichment of samples immunoprecipitated with the anti-IE 899 
antibody, respect to IgG control. Data from three experiments ± SEs. D) Both the wt and the mutant form 900 
40 
 
of -270 bp MICA promoter were used in ChIP experiments, and the relative enrichment compared. Data 901 
are expressed as percent of IE binding, with the relative enrichment of MICA -270 wt promoter set as 902 
100%, and are from three experiments ± SEs. E) ChIP assays on the endogenous MICA promoter were 903 
performed by transfecting IE1, IE2 or pSG5 vectors. Results are reported as described in panel C), and 904 
are from three independent experiments ± SEs. MIEP: major immediate early promoter; CRS: cis-905 
repression sequence.  906 
 907 
Figure 11. Effect of IE1 and IE2 on the transcriptional activity of PVR gene promoter. A) HFFs 908 
were transfected with pGL2-PVR (-571 bp fragment) promoter luciferase reporter vector, together with 909 
IE expression vectors, used alone or in combination, or pSG5. After 48 h, cells were harvested and 910 
luciferase activity was calculated as reported in figure 9. B, C) IE2-86 was replaced by IE2-55 (B) or by a 911 
zinc finger domain mutant of IE2-86 (IE2-Zn mut) (C), as described in figure 9. D) HFFs were transiently 912 
transfected with wild-type pGL2-PVR (-571 bp fragment) promoter luciferase reporter vector, or with 5’-913 
deletions constructs, together with IE expression vectors, or pSG5. After 48 h, cells were harvested and 914 
luciferase activity was calculated. Data from at least four experiments ± SEs. E) The effect of IE1 and 915 
IE2, alone or in combination, on PVR promoter deletions is shown. Data from at least four experiments ± 916 
SEs.  917 
Supplementary Figure 1. HCMV AD169 and TR strains stimulate expression of cell surface MICA. 918 
HFFswere grown to subconfluence and then infected with HCMV AD169 and TR (MOI of 1 PFU/cell), 919 
or mock infected (n.i.). At 4 dpi, cells were fixed and immunostained for MICA ligand, without 920 
permeabilization. Immunofluorescence experiments were repeated three times, and representative results 921 
are presented. Magnification: 60X. 922 
Supplementary Figure 2. Activation of DDR pathway after HCMV infection, and effect of the absence 923 
of 924 
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ATM on MICA, ULBP3 and PVR cell surface expression. A) HFFs were infected with HCMV AD169 925 
(MOI of 1 PFU/cell) or mock-infected (n.i.) and harvested at 3 dpi. Phospho-histone H2AX (γH2AX) 926 
(Ser139) expression levels were evaluated by FACS on cells stained with a specific FITC-conjugated 927 
mAb. A representative experiment of four performed at 3 dpi is shown. B) Data are presented as fold 928 
induction of γH2AX MFI values in HCMV-infected versus n.i. cells, set at 1. Data from four experiments 929 
± SEs. C) ATM-deficient (AT-/-) fibroblasts were mock-infected (n.i.) or infected with HCMV AD169 930 
(MOI of 1 PFU/cell). At different dpi, cells were harvested and ligand expression was analyzed as in 931 
figure 1. A representative experiment out of three is shown. D-G) HFFs were transiently transfected with 932 
siRNA specific for ATM (siATM) or with a non-targeting siRNA (siCtrl). 24 h later, cells were either 933 
mock-infected (n.i.) or infected with HCMV AD169 (MOI of 1 PFU/cell). At 2 dpi, cells and 934 
supernatants were harvested and assayed for ligand expression, percentage of IE+ cells, infectious virus 935 
production, and immunoblot analysis. D) Flow cytometry analysis of MICA, ULBP3 and PVR expression 936 
was performed as described in figure 1. Vertical dotted lines indicate the center of the peak for each 937 
ligand in not infected-siCtrl transfected cells. All panels derive from the same experiment, representative 938 
of three. E) The % of IE+ cells was analyzed by FACS on HCMV-infected cells stained intracellularly 939 
with a specific anti-IE mAb. F). Cell culture supernatants were assayed for infectious virus production by 940 
plaque assay. G) The levels of ATM protein expression were assayed by immunoblot analysis with a 941 
specific antibody. Immunodetection of the p85 subunit of PI-3K was used as a control of protein loading. 942 
ns: not statistically significant difference with Student’s t-test. 943 
Supplementary Figure 3. ATR or DNA-PK silencing does not affect MICA, ULBP3 and PVR 944 
expression. HFFs were transfected with siRNA specific for ATR (siATR) (panels A-D), DNA-PK 945 
(siDNA-PK) (panels E-H), or a non-targeting siRNA (siCtrl), and then infected and harvested as 946 
described in Fig. S3. A) and E) Flow cytometry analysis of MICA, ULBP3 and PVR expression was 947 
performed as described in figure 1. Vertical dotted lines indicate the center of the peak for each ligand in 948 
42 
 
not infected-siCtrl transfected cells. All panels in A) or E) derive from the same experiment, 949 
representative of three. B) and F) The % of IE+ cells was analyzed by FACS on HCMV-infected cells 950 
stained intracellularly with a specific anti-IE mAb. C) and G) Cell culture supernatants were assayed for 951 
infectious virus production by plaque assay. D) and H) The levels of ATR or DNA-PK protein expression 952 
were assayed by immunoblot analysis with a specific antibody. Immunodetection of the p85 subunit of 953 
PI-3K was used as a control of protein loading. ns: not statistically significant difference with Student’s t-954 
test. 955 
Supplementary Figure 4. Adenoviral-mediated overexpression of IE1 and IE2 proteins does not affect 956 
mRNA and cell surface expression of ULBP3. HFFs were transduced with adenoviral vectors (AdV) 957 
expressing IE1, IE2, or LacZ as a control, alone or in combination (total MOI 4 PFU/cell). Cells were 958 
harvested 24 h, 48 h or 72 h later, and analyzed for ligand mRNA and surface expression. A) Real-time 959 
PCR. Data from four experiments ± SEs, expressed as fold change units, were normalized with GAPDH 960 
and referred to not-transduced cells (-), considered as calibrators and set at 1. B) Cell surface expression 961 
levels of ULBP3 at 72 hpi, measured by FACS, are presented as MFI. Data from three experiments ± 962 
SEs. C) ULBP3 cell surface expression from a representative experiment performed at 72 hpi. 963 
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